SECRETORY LEUKOCYTE PROTEASE INHIBITOR DRY POWDER PHARMACEUTICAL COMPOSITIONS
First Claim
1. A pharmaceutical composition, comprising secretory leukocyte protease inhibitor (SLPI) protein and a pharmaceutically acceptable carrier, wherein said composition is a dry powder of less than about 10% by weight water, and wherein 50% to 95% by mass of said powder comprises particles or agglomerates of particles having a diameter within the range of from about 1.0 microns to about 8 microns with a mass median diameter ranging from about 3.0 microns to about 6 microns.
2 Assignments
0 Petitions
Accused Products
Abstract
The present invention relates to the pulmonary administration of a therapeutic protein by means of powdered pharmaceutical compositions suitable for inhalation therapy. In particular the invention relates to dry powder formulations of secretory leukocyte protease inhibitor (SLPI) for pulmonary delivery. Exemplary pharmaceutical compositions contain SLPI and a pharmaceutically acceptable carrier in the form of a dry powder which is typically less than about 10% by weight water. About 50% to 95% by mass of the powder comprises particles or agglomerates of particles having a diameter within the range of from about 1.0 microns to about 8 microns, with a mass median diameter ranging from about 3.0 microns to about 6 microns.
41 Citations
25 Claims
- 1. A pharmaceutical composition, comprising secretory leukocyte protease inhibitor (SLPI) protein and a pharmaceutically acceptable carrier, wherein said composition is a dry powder of less than about 10% by weight water, and wherein 50% to 95% by mass of said powder comprises particles or agglomerates of particles having a diameter within the range of from about 1.0 microns to about 8 microns with a mass median diameter ranging from about 3.0 microns to about 6 microns.
-
10. A pharmaceutical composition produced by the process comprising the steps of:
-
a) providing a mixture of secretory leukocyte protease inhibitor protein and optionally a pharmaceutically acceptable carrier in a solvent; and
b) spray drying said mixture to form a dry powder wherein said secretory leukocyte protease inhibitor comprises from about 50 to 100% by weight of the dry powder, wherein at least 50% to 95% by mass of the composition consists of particles or agglomerates of particles having a diameter within the range of from about 1.0 microns to about 8 microns with a mass median diameter ranging from about 3.0 microns to about 6 microns, and wherein the resulting composition is suitable for intratracheobronchial deposition. - View Dependent Claims (11, 12, 13, 14, 15, 16, 17, 18)
-
Specification